Portfolio companies

 


Octimet logo

OCTIMET Oncology NV is a new company that acts as a translational accelerator, focusing on creating value for investors and patients by providing rapid clinical proof of concept for cancer therapies through innovative clinical development strategies and patient centered biomarker approaches. OCTIMET was set-up in 2016 and is run by a highly experienced management team. The current focus is on its clinical stage asset OMO-1, a highly selective small molecule MET inhibitor that will be developed with specific biomarkers, whilst an additional late pre-clinical stage oncology asset 0MO-2 will also enter the portfolio. (www.octimet.com)


eTheRNA logo

eTheRNA was established in January 2013 as a spin-off company of the ‘Vrije Universiteit Brussel’ (VUB), following the development of the TriMix technology by the VUB Laboratory for Molecular and Cellular Therapy, headed by Prof. Kris Thielemans (and co-founders Carlo Heirman and Sonja van Meirvenne) in tandem with Prof Bart Neyns from the Brussels University Hospital ‘UZ Brussel’.

In 2015, eTheRNA entered into a partnership with Progress Pharma under the leadership of Dirk Reyn, former CEO of Movetis, who now heads eTheRNA immunotherapies management team. In July of that year, eTheRNA obtained from the VUB a worldwide exclusive license on the TriMix technology.

In March 2016, eTheRNA immunotherapies secured EUR 24 million in a Series, an investment with a strong international syndicate of investors.

This enables the company to continue the development of mRNA-based immunotherapies for melanoma, triple negative breast cancer and infectious diseases.


Novadip logo

Established in 2013, Novadip BioSciences is a biomedical spin-off company from the University of Louvain (UCL, Belgium) and its academic hospital, (Cliniques universitaires Saint-Luc). Novadip’s mission is to develop and bring to the market innovative treatments for large bone defects. The creation of NOVADIP is supported by the Louvain Technology Transfer Office (LTTO), Sopartec and VIVES II.

The lead product candidate of the Company is CREOST®

CREOST® introduces the principles of guided tissue regeneration based on stem cells from fatty tissue, associated to osteoinductive, osteoconductive and osteogenic properties to manufacture natural bone implants with the right shape, mineralization and all mechanical properties for replacement and repair of large bone defects.

CREOST® holds the potential for multiple indications including neurosurgery for spine, orthopaedic surgery for trauma, pseudarthrosis or tumour resection, cranial and maxillofacial surgery, Osteonecrosis, consequences of osteoporosis, etc.


Masthercell

 

Exit in January 2017


iteos

 

iTeos Therapeutics is a private biotechnology company targeting metabolism of the tumor microenvironment to develop small molecule immunomodulators for cancer treatments. iTeos is building its activities upon the unparalleled expertise of the Ludwig Cancer Research (LICR) – a world-class Research Institute in the fields of tumor immunology, therapeutic cancer vaccines, cancer biology and translational medicine in cancer. iTeos endeavours to develop small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standard of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints (e.g. anti-CTLA4, anti-PD1 and anti-PDL1 antibodies). Based in Gosselies, Belgium iTeos is a private company launched in 2012 as a spin-off of the Ludwig Cancer Research (LICR) and the de Duve Institute at the Université catholique de Louvain. iTeos raised €9,1M in 2012 from private investors, including LICR, Life Sciences Research Partners, Vives II, Hunza Ventures SCA, several high net worth individuals and from a Walloon government grant.


 

Promethera® Biosciences is a Belgian pharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatment based on allogeneic adult stem cell technology. Promethera® Biosciences’ mission is to discover, develop, and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells harvested from healthy human livers. Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type, the Heterologous Human Adult Liver Progenitor Cell (HHALPC):

  • Promethera® HepaStem, a unique cell therapy product, to treat severe diseases of the liver affecting children and adults. The innovation resides in both the simplicity of the treatment, which doesn’t require radical surgery (compared to liver transplantation), and in the wide variety of liver diseases that can be addressed with the same product.
  • Promethera® H2Screen and H3Screen, a unique cell model for the pharmaceutical industry to mimic metabolism and detoxification of new drugs by the human liver. The cell model is designed for the discovery and pre-clinical evaluation of new chemical entities.

ogeda-logo

Ogeda S.A. is a Belgium-based, private, Drug Discovery and Development company providing first-in-class small molecule drug candidates for unmet medical needs in multiple therapeutic areas. Ogeda has a worldwide recognized track-record for delivering of multiple innovative and proprietary small-molecules targeting GPCRs (G-Protein Coupled Receptors).

Ogeda is advancing its proprietary orally-available drug candidate ESN364 into clinical development for the treatment of Women’s Health Disorders. Phase I clinical trial on Male and Female Healthy Volunteers has been successfully completed in 2014, showing the good safety tolerance of ESN364, confirming its excellent pharmacokinetic profile and exhibiting its potential efficiency by acting on relevant hormonal biomarkers. Two Phase II clinical trials in UF and PCOS started on January 2015.

In addition, Ogeda advances other small molecules (preclinical stage) targeting GPCRs of interest for neurodegenerative diseases and inflammation.

Ogeda pursues a dual business model strategy of combining its internal program is for high value targets (Ogeda DRUG DISCOVERY) with its services business unit (Ogeda FAST) providing GPCR customized screening, cell lines and other services for biotech and pharmaceutical companies around the world.

Ogeda has also developed a broad target portfolio for licensing intellectual property rights to pharmaceutical companies for the development of therapeutic that act through GPCR targets.


qbio-logo

Q-Biologicals was acquired by the French Amatsi Group in January 2016.